Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
31 oct. 2024 16h00 HE | Lyell Immunopharma, Inc
Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
24 oct. 2024 16h00 HE | Lyell Immunopharma, Inc
Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 in...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
04 oct. 2024 09h00 HE | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
24 sept. 2024 16h05 HE | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Announces Participation in September Investor Conferences
28 août 2024 16h05 HE | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
07 août 2024 16h05 HE | Lyell Immunopharma, Inc
Reported dose-dependent antitumor clinical activity in patients with relapsed/refractory triple-negative breast cancer from the Phase 1 trial of LYL797, a ROR1-targeted Chimeric Antigen Receptor (CAR)...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
26 juin 2024 07h00 HE | Lyell Immunopharma, Inc
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
03 juin 2024 16h05 HE | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
07 mai 2024 16h05 HE | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
06 mai 2024 08h00 HE | Lyell Immunopharma, Inc
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the...